Logo image of NTLA

INTELLIA THERAPEUTICS INC (NTLA) Stock Overview

USA - NASDAQ:NTLA - US45826J1051 - Common Stock

16.78 USD
+0.47 (+2.88%)
Last: 9/29/2025, 11:41:08 AM

NTLA Key Statistics, Chart & Performance

Key Statistics
52 Week High21.47
52 Week Low5.9
Market Cap1.80B
Shares107.35M
Float102.00M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-4.69
PEN/A
Fwd PEN/A
Earnings (Next)11-05 2025-11-05/bmo
IPO05-06 2016-05-06
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


NTLA short term performance overview.The bars show the price performance of NTLA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 20 40 60 80 100

NTLA long term performance overview.The bars show the price performance of NTLA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of NTLA is 16.78 USD. In the past month the price increased by 40.6%. In the past year, price decreased by -22.33%.

INTELLIA THERAPEUTICS INC / NTLA Daily stock chart

NTLA Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.92 391.43B
AMGN AMGEN INC 12.53 147.08B
GILD GILEAD SCIENCES INC 14.45 138.78B
VRTX VERTEX PHARMACEUTICALS INC 23.03 100.01B
REGN REGENERON PHARMACEUTICALS 12.26 59.30B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.17B
ARGX ARGENX SE - ADR 77.33 43.87B
ONC BEONE MEDICINES LTD-ADR 5.8 39.33B
INSM INSMED INC N/A 29.82B
BNTX BIONTECH SE-ADR N/A 23.75B
NTRA NATERA INC N/A 22.47B
BIIB BIOGEN INC 8.57 20.12B

About NTLA

Company Profile

NTLA logo image Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 403 full-time employees. The company went IPO on 2016-05-06. CRISPR is a gene editing technology which is also sometimes referred to as CRISPR/Cas or CRISPR/Cas9 when referring to the use of CRISPR technology with the Cas9 enzyme. Its in vivo product candidates address genetic diseases by deploying its technologies, including CRISPR/Cas9 delivered by LNPs, as the therapy for diseases with high unmet need. Its lead in vivo product candidates, nexiguran ziclumeran (nex-z or NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis and NTLA-2002 for the treatment of hereditary angioedema (HAE), are the first CRISPR-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. For its ex vivo product candidates, it applies its technologies to create engineered cell therapies to address immuno-oncology and autoimmune diseases.

Company Info

INTELLIA THERAPEUTICS INC

40 Erie St Ste 130

Cambridge MASSACHUSETTS 02139 US

CEO: John M. Leonard

Employees: 403

NTLA Company Website

NTLA Investor Relations

Phone: 18572856200

INTELLIA THERAPEUTICS INC / NTLA FAQ

What is the stock price of INTELLIA THERAPEUTICS INC today?

The current stock price of NTLA is 16.78 USD. The price increased by 2.88% in the last trading session.


What is the ticker symbol for INTELLIA THERAPEUTICS INC stock?

The exchange symbol of INTELLIA THERAPEUTICS INC is NTLA and it is listed on the Nasdaq exchange.


On which exchange is NTLA stock listed?

NTLA stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INTELLIA THERAPEUTICS INC stock?

33 analysts have analysed NTLA and the average price target is 34.82 USD. This implies a price increase of 107.5% is expected in the next year compared to the current price of 16.78. Check the INTELLIA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INTELLIA THERAPEUTICS INC worth?

INTELLIA THERAPEUTICS INC (NTLA) has a market capitalization of 1.80B USD. This makes NTLA a Small Cap stock.


How many employees does INTELLIA THERAPEUTICS INC have?

INTELLIA THERAPEUTICS INC (NTLA) currently has 403 employees.


What are the support and resistance levels for INTELLIA THERAPEUTICS INC (NTLA) stock?

INTELLIA THERAPEUTICS INC (NTLA) has a support level at 12.37. Check the full technical report for a detailed analysis of NTLA support and resistance levels.


Is INTELLIA THERAPEUTICS INC (NTLA) expected to grow?

The Revenue of INTELLIA THERAPEUTICS INC (NTLA) is expected to grow by 15.31% in the next year. Check the estimates tab for more information on the NTLA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INTELLIA THERAPEUTICS INC (NTLA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INTELLIA THERAPEUTICS INC (NTLA) stock pay dividends?

NTLA does not pay a dividend.


When does INTELLIA THERAPEUTICS INC (NTLA) report earnings?

INTELLIA THERAPEUTICS INC (NTLA) will report earnings on 2025-11-05, before the market open.


What is the Price/Earnings (PE) ratio of INTELLIA THERAPEUTICS INC (NTLA)?

INTELLIA THERAPEUTICS INC (NTLA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.69).


What is the Short Interest ratio of INTELLIA THERAPEUTICS INC (NTLA) stock?

The outstanding short interest for INTELLIA THERAPEUTICS INC (NTLA) is 27.19% of its float. Check the ownership tab for more information on the NTLA short interest.


NTLA Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to NTLA. When comparing the yearly performance of all stocks, NTLA is one of the better performing stocks in the market, outperforming 83.09% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NTLA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NTLA. While NTLA seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NTLA Financial Highlights

Over the last trailing twelve months NTLA reported a non-GAAP Earnings per Share(EPS) of -4.69. The EPS increased by 14.42% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -53.42%
ROE -67.14%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%35.53%
Sales Q2Q%104.76%
EPS 1Y (TTM)14.42%
Revenue 1Y (TTM)-37.19%

NTLA Forecast & Estimates

33 analysts have analysed NTLA and the average price target is 34.82 USD. This implies a price increase of 107.5% is expected in the next year compared to the current price of 16.78.

For the next year, analysts expect an EPS growth of 20.11% and a revenue growth 15.31% for NTLA


Analysts
Analysts80.61
Price Target34.82 (107.51%)
EPS Next Y20.11%
Revenue Next Year15.31%

NTLA Ownership

Ownership
Inst Owners88.25%
Ins Owners1.43%
Short Float %27.19%
Short Ratio6.1